Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer’s disease

Bibliography

• Hebert LE, Weuve J, Scherr PA, et al. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology 2013;80:1778–83
   PubMed Web of Science ®Google Scholar
• Beach TG. Alzheimer’s disease and the “Valley Of Death”: not enough guidance from human brain tissue? J Alzheimers Dis 2013;33(Suppl 1):S219–33
   PubMedGoogle Scholar
• Bloom GS. Amyloid-beta and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol 2014;71:505–8
   PubMed Web of Science ®Google Scholar
• Glenner GG, Wong CW. Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984;120:885–90
   PubMed Web of Science ®Google Scholar
• Tanzi RE, Gusella JF, Watkins PC, et al. Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science 1987;235:880–4
   PubMed Web of Science ®Google Scholar
• Sabbagh MN, Galasko D, Koo E, et al. Amyloid-beta and treatment opportunities for Alzheimer’s disease. J Alzheimers Dis 2000;2:231–59
   PubMedGoogle Scholar
• McGeer PL, McGeer EG. The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathol 2013;126:479–97
   PubMed Web of Science ®Google Scholar
• Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med 2010;362:329–44
   PubMed Web of Science ®Google Scholar
• Morgan D, Diamond DM, Gottschall PE, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature 2000;408:982–5
   PubMed Web of Science ®Google Scholar
• Zotova E, Bharambe V, Cheaveau M, et al. Inflammatory components in human Alzheimer’s disease and after active amyloid-beta42 immunization. Brain 2013;136:2677–96
   PubMed Web of Science ®Google Scholar
• Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med 2014;370:322–33
   PubMed Web of Science ®Google Scholar
• Yan SD, Chen X, Fu J, et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer’s disease. Nature 1996;382:685–91
   PubMed Web of Science ®Google Scholar
• Takeuchi M, Yamagishi S. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer’s disease. Curr Pharm Des 2008;14:973–8
   PubMed Web of Science ®Google Scholar
• Vicente MH, Outeiro TF. The sour side of neurodegenerative disorders: the effects of protein glycation. J Pathol 2010;221:13–25
   PubMed Web of Science ®Google Scholar
• Yan SD, Chen X, Schmidt AM, et al. Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc Natl Acad Sci USA 1994;91:7787–91
   PubMed Web of Science ®Google Scholar
• Neeper M, Schmidt AM, Brett J, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992;267:14998–5004
   PubMed Web of Science ®Google Scholar
• Schmidt AM, Yan SD, Wautier JL, et al. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999;84:489–97
   PubMed Web of Science ®Google Scholar
• Chen X, Walker DG, Schmidt AM, et al. RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer’s disease. Curr Mol Med 2007;7:735–42
   PubMed Web of Science ®Google Scholar
• Srikanth V, Maczurek A, Phan T, et al. Advanced glycation endproducts and their receptor RAGE in Alzheimer’s disease. Neurobiol Aging 2011;32:763–77
   PubMed Web of Science ®Google Scholar
• Nozaki I, Watanabe T, Kawaguchi M, et al. Reduced expression of endogenous secretory receptor for advanced glycation endproducts in hippocampal neurons of Alzheimer’s disease brains. Arch Histol Cytol 2007;70:279–90
   PubMed Web of Science ®Google Scholar
• Zhang L, Postina R, Wang Y. Ectodomain shedding of the receptor for advanced glycation end products: a novel therapeutic target for Alzheimer’s disease. Cell Mol Life Sci 2009;66:3923–35
   PubMed Web of Science ®Google Scholar
• Ghidoni R, Benussi L, Glionna M, et al. Decreased plasma levels of soluble receptor for advanced glycation end products in mild cognitive impairment. J Neural Transm 2008;115:1047–50
   PubMed Web of Science ®Google Scholar
• Lee EJ, Park JH. Receptor for advanced glycation endproducts (RAGE), its ligands, and soluble rage: potential biomarkers for diagnosis and therapeutic targets for human renal diseases. Genomics Inform 2013;11:224–9
   PubMedGoogle Scholar
• Miller MC, Tavares R, Johanson CE, et al. Hippocampal RAGE immunoreactivity in early and advanced Alzheimer’s disease. Brain Res 2008;1230:273–80
   PubMed Web of Science ®Google Scholar
• Sasaki N, Toki S, Chowei H, et al. Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer’s disease. Brain Res 2001;888:256–62
   PubMed Web of Science ®Google Scholar
• Lue LF, Walker DG, Brachova L, et al. Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer’s disease: identification of a cellular activation mechanism. Exp Neurol 2001;171:29–45
   PubMed Web of Science ®Google Scholar
• Arancio O, Zhang HP, Chen X, et al. RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J 2004;23:4096–105
   PubMed Web of Science ®Google Scholar
• Fang F, Lue LF, Yan S, et al. RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer’s disease. FASEB J 2010;24:1043–55
   PubMed Web of Science ®Google Scholar
• Origlia N, Criscuolo C, Arancio O, et al. RAGE inhibition in microglia prevents ischemia-dependent synaptic dysfunction in an amyloid-enriched environment. J Neurosci 2014;34:8749–60
   PubMed Web of Science ®Google Scholar
• Deane R, Du YS, Submamaryan RK, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003;9:907–13
   PubMed Web of Science ®Google Scholar
• Deane R, Wu Z, Sagare A, et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 2004;43:333–44
   PubMed Web of Science ®Google Scholar
• Donahue JE, Flaherty SL, Johanson CE, et al. RAGE, LRP-1, and amyloid-beta protein in Alzheimer’s disease. Acta Neuropathol 2006;112:405–15
   PubMed Web of Science ®Google Scholar
• Jeynes B, Provias J. Evidence for altered LRP/RAGE expression in Alzheimer lesion pathogenesis. Curr Alzheimer Res 2008;5:432–7
   PubMed Web of Science ®Google Scholar
• Deane R, Bell RD, Sagare A, et al. Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer’s disease. CNS Neurol Disord Drug Targets 2009;8:16–30
   PubMed Web of Science ®Google Scholar
• Deane R, Sagare A, Zlokovic BV. The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer’s disease. Curr Pharm Des 2008;14:1601–5
   PubMed Web of Science ®Google Scholar
• Sabbagh MN, Agro A, Bell J, et al. PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease. Alzheimer Dis Assoc Disord 2011;25:206–12
   PubMed Web of Science ®Google Scholar
• Deane R, Singh I, Sagare AP, et al. A multimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest 2012;122:1377–92
   PubMed Web of Science ®Google Scholar
• Carnevale D, Mascio G, D’Andrea I, et al. Hypertension induces brain beta-amyloid accumulation, cognitive impairment, and memory deterioration through activation of receptor for advanced glycation end products in brain vasculature. Hypertension 2012;60:188–97
   PubMed Web of Science ®Google Scholar
• Burstein AH, Grimes I, Galasko DR, et al. Effect of TTP488 in patients with mild to moderate Alzheimer’s disease. BMC Neurol 2014;14:12
   PubMedGoogle Scholar
• Galasko D, Bell J, Mancuso J, et al. for the ADCS. Clinical trial of an inhibitor of RAGE-Abeta interactions in Alzheimer’s disease. Neurology 2014;82(17):1536–42
   PubMed Web of Science ®Google Scholar
• Castellani RJ, Smith MA. Compounding artefacts with uncertainty, and an amyloid cascade hypothesis that is ‘too big to fail’. J Pathol 2011;224(2):147–52
   PubMed Web of Science ®Google Scholar